Sanofi Consumer Healthcare India Ltd (SANOFICONR) Q1 FY27 Results Analysis: EBITDA Margin Expands 611 bps, PAT Grows 23.7%
Sanofi Consumer Healthcare India Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 235.70 Cr (+6.70% YoY) and PAT growth of +13.30% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 28, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 235.70 Cr (+6.70% YoY) |
| PAT (Q1) | Rs. 68.80 Cr (+13.30% YoY) |
| EBITDA margin | 37.89% (+611 bps YoY) |
| EPS (Q1) | Rs. 29.87 (+13.30% YoY) |
| Market cap | Rs. 10,858.01 Cr |
| CMP | Rs. 4,707.20 |
Quarter Snapshot
Sanofi Consumer Healthcare India reported Q1 FY27 with EBITDA margin expanding 611 bps YoY to 37.89% and normalized PAT growing 23.7% YoY, driven by raw material tailwinds and operating leverage. Domestic sales grew 12% YoY aided by product relaunches, though overall revenue growth of 6.7% lagged the IPM due to export decline. Strong cash generation and a net cash balance sheet provide financial flexibility.
Key Investment Insights
Key Positives
- EBITDA margin expanded 611 bps YoY to 37.89%
- Normalized PAT grew 23.7% YoY
- Operating cash flow for H1 FY27 improved to Rs.109.6 Cr from Rs.17.9 Cr in H1 FY26
- Domestic sales grew 12% YoY aided by product relaunch
- Free cash flow of Rs.108.8 Cr in H1 FY27
Risk Factors
- Overall revenue growth of 6.7% YoY trailed IPM growth of 12.1%, implying export sales likely declined
- Trade receivables rose 68% to Rs.49.8 Cr and inventories rose 51.4% to Rs.93.7 Cr, indicating working capital build
- Sequentially, EBITDA margin contracted 85 bps from Q4FY26's 38.74% to 37.89% as other expenses grew faster than revenue
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.